- NurExone Biologic (NRX) shows how its platform technology for loading exosomes with therapeutic molecules works
- The company develops a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries
- Loaded exosomes are biologically guided to target inflamed tissues to create a healing environment
- NurExone intends to monetize its proprietary technology platform
- In the near future, the company will explore potential licensing opportunities for its loading technique once it is finalized
- NurExone Biologic (NRX) is trading at C$0.38 at 3:43 pm as of November 16
NurExone Biologic (NRX) reports that based on a pre-clinical loading efficiency study, its loading technology can load therapeutic molecular cargo into exosomes.
The company develops a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
In exosome-based therapies, loaded exosomes are biologically guided to target inflamed tissues to “dock” and unload their therapeutic cargo, creating a healing environment.
The company’s platform for exosome-based therapy production is planned to include large-scale exosome production, a therapeutic cargo and unique technology to load the therapeutic cargo.
Previous research results and initiatives have shown the efficiency of its large-scale exosome production process and the effectiveness of this proprietary small-interfering RNA sequence as a therapeutic cargo.
Perhaps one of the most important studies showed that NurExone was able to conduct the desired loading efficiency without compromising the functionality of the loaded molecular cargo.
NurExone intends to monetize its proprietary technology platform.
In the near future, the company will explore potential licensing opportunities for its loading technique once it is finalized.
Dr. Lior Shaltiel, CEO of NurExone, commented, “Realizing the promise of exosome-based therapies requires efficient technology for loading therapeutic molecules into the exosome nanocarriers.”
“We believe that our innovative and exclusive loading technology overcomes this industry hurdle, which enables us to capitalize on potential technology platform licensing opportunities and the commercialization of our ExoTherapy products produced thereby,” added Dr. Shaltiel.
For the potential treatment of patients with traumatic spinal cord injury patients, NurExone hopes to use its ExoTherapy’s proprietary exosomes as biologically-guided nanocarriers to deliver specialized siRNA therapeutic compounds to target areas.
The delivered molecules promote an environment that induces a healing process at the target location.
NurExone’s technology achieves over 62 per cent loading efficiency, showing substantial equivalence to the control process, which is just under 60 per cent.
So far, ExoTherapy has been conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology.
NurExone Biologic (NRX) is trading at C$0.38 at 3:43 pm as of November 16.
